Viking Therapeutics

Major readouts on the horizon for small developers
Major readouts on the horizon for small developers
EP Vantage
Aldeyra Therapeutics
Autolus Therapeutics
Bavarian Nordic
BioXcel Therapeutics
Disc Medicine
Editas Medicine
Immunogen
Lantheus
Mersana Therapeutics
NGM Biopharmaceuticals
Omeros
Roche
Sutro BioPharma
uniQure
Valneva
Viking Therapeutics
Flag link:
Viking sets ships toward phase 2 after obesity med passes early test
Viking sets ships toward phase 2 after obesity med passes early test
Fierce Biotech
Viking Therapeutics
obesity
clinical trials
VK2735
Flag link:
Spotlight – What is next in Nash
Spotlight – What is next in Nash
EP Vantage
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Flag link:
Catalysts ahead for the smaller players
Catalysts ahead for the smaller players
EP Vantage
89Bio
Altimmune
AnaptysBio
BioXcel Therapeutics
Calliditas Therapeutics
Eli Lilly
Esperion Therapeutics
Geron
Nektar Therapeutics
Oramed Pharmaceuticals
Pliant Therapeutics
Replimune
Selecta Biosciences
Swedish Orphan Biovitrum
Vera Therapeutics
Viking Therapeutics
Flag link:
1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial
1b, or not 1b: FDA hits Viking with clinical hold over mix-up in phase of rare disease trial
Fierce Biotech
Viking Therapeutics
clinical trials
FDA
VK0214
metabolic disorders
Flag link:
Viking Therapeutics’ NASH Therapy Shows Major Reduction of Liver Fat and LDL Cholesterol
Viking Therapeutics’ NASH Therapy Shows Major Reduction of Liver Fat and LDL Cholesterol
BioSpace
Viking Therapeutics
NASH
VK2809
Flag link:
NASH drugmaker stocks rebound after dip on FDA guidance
NASH drugmaker stocks rebound after dip on FDA guidance
Biopharma Dive
NASH
FDA
Madrigal Pharmaceuticals
Viking Therapeutics
Intercept Pharma
Genfit
Flag link:
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Here's Why Madrigal Pharmaceuticals Fell 39.4% in November
Motley Fool
Madrigal Pharmaceuticals
NASH
MGL-3196
Viking Therapeutics
VK2809
Flag link:
3 Biotech Stocks That Soared This Week
3 Biotech Stocks That Soared This Week
Motley Fool
Viking Therapeutics
Acadia Pharmaceuticals
Corbus Pharmaceuticals
Flag link:
Promising study results thrust Viking Therapeutics into race for lucrative fatty liver disease treatment
Promising study results thrust Viking Therapeutics into race for lucrative fatty liver disease treatment
Stat
Viking Therapeutics
NASH
non-alcoholic fatty liver disease
VK2809
clinical trials
Flag link:
2 Biotech Stocks Poised for Jaw-Dropping Growth
2 Biotech Stocks Poised for Jaw-Dropping Growth
Motley Fool
Geron
Viking Therapeutics
imetelstat
VK5211
Flag link:
3 Biotech Stocks With Big News Coming in NASH
3 Biotech Stocks With Big News Coming in NASH
Motley Fool
NASH
Viking Therapeutics
Gilead Sciences
Intercept Pharma
VK2809
Ocalivia
selonsertib
Flag link:
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers
Motley Fool
NASH
liver disease
Viking Therapeutics
Madrigal Pharmaceuticals
Pfizer
Bristol-Myers Squibb
Gilead Sciences
Flag link:
Viking Therapeutics Shares Double Amid No News
Viking Therapeutics Shares Double Amid No News
Yahoo/Benzinga
Viking Therapeutics
Flag link:
Biotech Ligand Gets Sweeter Deal From Partner Viking
Biotech Ligand Gets Sweeter Deal From Partner Viking
Investors.com
Ligand Pharmaceuticals
Viking Therapeutics
IPOs
Flag link: